Reading Room

Recommendations for Contraceptive Use

Previous PageNext PageTable Of Contents


Combined Oral Contraceptives (COCs)


Q.2. When can COCs be started postpartum?

Recommendations

Rationales

For Breastfeeding Women: (These restrictions do not apply to women who are only doing token, i.e., minimal, breastfeeding.)  
a) COCs should not be used in the first 6 weeks postpartum. COCs are considered by many experts to be the method of LAST choice during any state of lactation, especially in the first 6 weeks to 6 months.

b) After 6 to 8 weeks postpartum, breastfeeding women desiring hormonal contraception should be encouraged to use progestin-only pills (POPs) or injectables or NORPLANT® Implants. (Before 6 to 8 weeks postpartum, there is no risk of conception for a fully or nearly fully breastfeeding woman - see How to Be Reasonably Sure the Woman Is Not Pregnant.)

a-b) Even low dose (30 to 35 mcg) COCs decrease breastmilk production.
  1. WHO Task Force on Oral Contraceptives. Effects of hormonal contraceptives on milk volume and infant growth. Contraception 1984;30(6):505-521.
   
c) If COCs remain the method of choice, but the woman chooses to rely on the Lactational Amenorrhea Method (LAM) initially, start COCs when her menses return,** or when the woman is no longer fully or nearly fully breastfeeding or at 6 months postpartum, whichever comes first. COC packets may be given to the woman before this time to ensure that she is able to start the method when she needs to.

**In breastfeeding women, bleeding in the first 56 days (8weeks) postpartum is NOT considered "menstrual" bleeding, because it is not preceded by ovulation.

c) For fully breastfeeding women, there is no known advantage to initiating COCs during LAM or while the LAM criteria apply.
  1. Kennedy KI. Breastfeeding and the double protection dilemma. Family Health International, September 1991.
  2. Labbok M, Cooney K, Coly S. Guidelines: Breastfeeding, Family Planning, and the Lactational Amenorrhea Method - LAM. Washington, DC: Institute for Reproductive Health, 1994.

In fact, initiating COCs before they are necessary may be a disadvantage because COCs have a detrimental effect on breastmilk volume and composition, which may affect the infant's health and growth.

  1. WHO Task Force on Oral Contraceptives. Effects of hormonal contraceptives on milk volume and infant growth. Contraception 1984; 30(6):505-521.
  2. WHO Task Force on Oral Contraceptives. Special Programme of Research, Development, and Research Training in Human Reproduction. Effects of hormonal contraceptives on breast milk composition and infant growth. Studies in Family Planning 1988; 19(6):361-369.
   
d) If she does not want to rely on LAM but is breastfeeding, she should be advised to choose a non-estrogenic method. If she still makes an informed choice to use COCs, they can be started anytime after the first 8 to 12 weeks postpartum if she is still amenorrheic, or whenever the service provider can be reasonably sure that the woman is not pregnant. d) Even low dose (30 to 35 mcg) COCs decrease breastmilk production. Waiting at least 8 to 12 weeks postpartum permits breastfeeding to be better established. Whether exposure of the neonate (in the first 8 weeks) to exogenous estrogens and progestins may, in theory, affect neonatal growth and development is a question under study.
   
For Non-Breastfeeding Women:  
a) If not breastfeeding, a woman can begin COCs after the second to third postpartum week. a) Blood coagulation and fibrinolysis are essentially normalized by 3 weeks postpartum (and are close to normal at 2 weeks postpartum).
  1. Dahlman T, Hellgren M, Blombäck M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecologic and Obstetric Investigation 1985;20(1):37-44.

Any part of Recommendations for Updating Selected Practices in Contraceptive Use may be reproduced or adapted to meet local needs without prior permission from the TG/CWG Secretariat, provided the TG/CWG is acknowledged and the material is made available free of charge or at cost.


| Home | Family Planning | Maternal & Neonatal Health | Cervical CancerRelated Health Topics
Tools for Trainers
| Reading Room | Related Links | Search ReproLine | Website Tools

Quick Search 

Website design copyright © 1995-2003 by JHPIEGO Corporation. All rights reserved.

Last Updated: 09 Jul 2003

URL: http://www.reproline.jhu.edu/
Reproductive Health Online (ReproLine): a family planning and reproductive health training website

Top Of Page